Calithera Biosciences

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance immune-cell activity. The company, founded in 2010, is committed to rigorous science and has a passion for improving the lives of people impacted by cancer and other life-threatening diseases. Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients in the biotechnology, health and wellness, and pharmaceutical industries. The company is headquartered in the United States. Its last investment, a Post-IPO Equity investment, took place on 30 March 2022. However, specific information about the investors involved in this round is not available. With its focus on targeting cancer differently, Calithera Biosciences presents an intriguing opportunity for potential venture capital interest.